Premium
Identification of complement C3f‐desArg and its derivative for acute leukemia diagnosis and minimal residual disease assessment
Author(s) -
Liang Tingting,
Wang Na,
Li Wei,
Li Ailing,
Wang Jie,
Cui Jiuwei,
Liu Nian,
Li Yan,
Li Ling,
Yang Guozi,
Du ZhongHua,
Li Dan,
He Kun,
Wang Guanjun
Publication year - 2009
Publication title -
proteomics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.26
H-Index - 167
eISSN - 1615-9861
pISSN - 1615-9853
DOI - 10.1002/pmic.200900513
Subject(s) - minimal residual disease , complement (music) , leukemia , medicine , biomarker , peptide , oncology , immunology , biology , gene , biochemistry , phenotype , complementation
Therapeutic conditions for acute leukemia (AL) mainly rely on diagnosis and detection of minimal residual disease (MRD). However, no serum biomarker has been available for clinicians to make diagnosis of AL and assessment of MRD. In this study, we performed bead fractionation/MALDI‐TOF‐MS analysis on sera from patients with AL. Support vector machine algorithm was used to obtain diagnostic model that discriminated proteomic spectra of patients with AL from that of controls. Twenty‐six features with p <0.00001 had optimal discriminatory performance, with 97% sensitivity and 100% specificity. Statistical analysis revealed that two peptides with m / z 1778 and 1865 were gradually decreased in their relative intensities with increase of remission degree. Moreover, the peptide with m / z 1865 was also found to be correlated with AL types. With FT‐ICR‐MS detection, both the peptides were identified as fragments of complement C3f. Linear regression analysis showed that the combined use of them could discriminate PML/RARα positive M3 from molecular remission M3. Two fragments of complement C3f were significantly correlated with MRD levels and could be used for clinical practice in MRD assessment.